戻る Agendas
[V1-S1-S2] What Can Japan Do for Global Medicine Development?
Session Chair(s)
Akihisa Harada, MD, PhD
President
Pfizer Japan Inc., Japan
Tatsuo Kurokawa, DIAFellow, PhD
Director General
The Japan Biosimilar Association, Japan
Japan medical system has been highly rated by WHO World Health Report because of Japanese unique universal care system and accessibility to hospital, and has achieved a goal of providing highquality medical service with patients. On the other hand, medical science and advanced medicine technology are making remarkable advance, and they will lead to not only academic medical research but also new medical treatment, and will expected to contribute to global and citizen’s medicine. Consider what Japan can do for the global medicine in the field of national health by using Japanese medical and research infrastructure. According to the relief of device/drug lag in Japan, now Japan approach for regenerative medicine and drug development is catching up and is going to overtake US/EU Given the situation, in this session, speakers and panelists from regulatory, industry and academia perspective would discuss what are Japanese strengths and how Japan can play an important role in a field of global medicine development.
Speaker(s)
Healthcare and Medical Research in the Information Age
Ryozo Nagai, MD, PhD
Jichi Medical University, Japan
President
Moving Forward for the Public Health Around the World - PMDA’s Challenges-
Tatsuya Kondo, MD, PhD
SH Medical Excellence JAPAN, Japan
President
Toward Acceleration of Innovative Drug Discovery
Masafumi Nogimori
Astellas Pharma Inc., Japan
Representative Director, Chairman of the Board
Realizing Japan’s potential in global drug development
Carsten Brunn, PhD
Bayer Yakuhin, Ltd., Japan
President and Representative Director